PacBio's shares skyrocketed 76 percent in November on the news that Illumina plans to acquire the firm for $1.2 billion in cash.
The firm saw growth of 8 percent in its life science business, 9 percent in its crosslabs group, and 9 percent in its diagnostics and genomics division in Q4.
The company said testing services revenues more than doubled during the quarter as its AlloSure kidney transplant diagnostic continued to penetrate the market.
MDx revenues increased 3 percent to $158.0 million, but excluding non-recurring royalty revenue in the prior-year period, MDx revenues increased 10 percent.
Myriad CEO Mark Capone said earnings during the quarter exceeded expectations based on strong volume growth from hereditary cancer and new products.
Total revenues were down due to lower assay revenues, which shrank 11 percent from a year ago. Sample-to-answer molecular product revenues grew 15 percent.
The company said it saw the biggest revenue growth in its instruments business, which gained 32 percent year over year.
After six straight months of gains, the index saw a sharp drop in October that even positive earnings news could not stave off.
Test volume for the firm's Cologuard colorectal cancer screening test rose 49 percent year over year during the quarter.
The firm beat analysts' revenue expectations for the quarter while its net loss was in line with predictions.
The New York Times reports on an effort to address in high school biology classes misconceptions regarding race and genetics.
60 Minutes speaks with Harvard's George Church about tackling the effects of aging and more.
In PLOS this week: rare alterations in Timothy syndrome, analysis of twins' gut microbiomes, and more.
GenomeWeb reports that Veritas Genetics is suspending its US operations.